Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1849 Target Snapshot

Enoyl-[acyl-carrier-protein] reductase [NADH] · SINGLE PROTEIN · Mycobacterium tuberculosis

Back to Search Search this target Browse approvals Evidence Card
971Compounds
204Assays
5Approved Drugs
603.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Enoyl-[acyl-carrier-protein] reductase [NADH] shows approved-linked disease relevance led by pulmonary tuberculosis. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P9WGR1. Start with pulmonary tuberculosis, then reuse UniProt P9WGR1 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with pulmonary tuberculosis, then reuse UniProt P9WGR1 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
pulmonary tuberculosis

Enoyl-[acyl-carrier-protein] reductase [NADH] shows approved-linked disease relevance led by pulmonary tuberculosis. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with pulmonary tuberculosis because it currently carries approved-linked support. Linked drugs include ETHIONAMIDE, ISONIAZID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Enoyl-[acyl-carrier-protein] reductase [NADH] as ChEMBL target CHEMBL1849, mapped to UniProt P9WGR1. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Enoyl-[acyl-carrier-protein] reductase [NADH]
SINGLE PROTEIN · Mycobacterium tuberculosis
As of 2026-09-14
ChEMBL target ID
CHEMBL1849
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P9WGR1
Enoyl-[acyl-carrier-protein] reductase [NADH]
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Enoyl-[acyl-carrier-protein] reductase [NADH] is the right protein anchor across sources, using UniProt P9WGR1 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why pulmonary tuberculosis is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameEnoyl-[acyl-carrier-protein] reductase [NADH]
Target TypeSINGLE PROTEIN
OrganismMycobacterium tuberculosis
UniProtP9WGR1
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelEnoyl-[acyl-carrier-protein] reductase [NADH]
UniProt AccessionP9WGR1
Component TypeProtein
Sequence Length269 aa

Enoyl-[acyl-carrier-protein] reductase [NADH]

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Enoyl-[acyl-carrier-protein] reductase [NADH], mapped to UniProt P9WGR1. Sequence length is 269 aa.

Mapped IDP9WGR1
Review nameEnoyl-[acyl-carrier-protein] reductase [NADH]
OrganismMycobacterium tuberculosis
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Enoyl-[acyl-carrier-protein] reductase [NADH] shows approved-linked disease relevance led by pulmonary tuberculosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
pulmonary tuberculosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugETHIONAMIDE
Linked drugISONIAZID
Approved-linked Approved
tuberculosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugETHIONAMIDE
Linked drugISONIAZID
Approved-linked Approved
HIV infection
1 linked drug · 1 direct · 1 efficacy
Linked drugISONIAZID
Approved-linked Approved
silicosis
1 linked drug · 1 direct · 1 efficacy
Linked drugISONIAZID
Late clinical Phase III
meningitis
1 linked drug · 1 direct · 1 efficacy
Linked drugISONIAZID
Clinical signal Phase II
multidrug-resistant tuberculosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugETHIONAMIDE
Linked drugISONIAZID
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with pulmonary tuberculosis because it currently carries approved-linked support. Linked drugs include ETHIONAMIDE, ISONIAZID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasepulmonary tuberculosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

5
Approved
Assay Mix

Activity Type Distribution

IC50488.0
KI86.0
KD29.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1236225 10.66 Ki 0.022 Preclinical
CHEMBL4177124 9.7 Ki 0.2 Preclinical
CHEMBL2311561 9.12 Ki 0.75 Preclinical
CHEMBL4174518 9.12 Ki 0.75 Preclinical
CHEMBL64 9.12 Ki 0.75 Approved
CHEMBL4162007 9.02 Ki 0.96 Preclinical
CHEMBL258931 9.0 Ki 1.0 Preclinical
CHEMBL258932 9.0 Ki 1.0 Preclinical
CHEMBL258933 9.0 Ki 1.0 Preclinical
CHEMBL259138 9.0 Ki 1.0 Preclinical
Distribution

pChEMBL Value Distribution

98
5.0
46
5.5
63
6.0
61
6.5
28
7.0
32
7.5
23
8.0
12
8.5
31
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

TRICLOSAN
CHEMBL849
Approved 1997
Properties Compare Identifier
RIFAMPIN
CHEMBL374478
Approved 1971
Properties Compare Identifier
ISONIAZID
CHEMBL64
Approved 1952
Properties Compare Identifier
Assay Landscape

Assay Landscape

204
Total Assays
367
Tested Compounds
1
Assay Types
Binding — 204 assays, 367 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 156 294 6.4
assay format 42 71 5.4
cell-based format 6 2 6.4

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine